The Evolution of Ketamine Research in Psychiatry

The investigation of ketamine as a psychiatric treatment spans over two decades and has generated one of the most active areas of research in modern psychopharmacology.

Foundational Studies

Berman et al. (2000) — The First Signal

The first published RCT of ketamine for depression was conducted at Yale University. Seven patients received a single IV infusion (0.5 mg/kg over 40 minutes) in a crossover design. Results showed significant mood improvement within 72 hours.

Significance: First demonstration that NMDA antagonism could produce rapid antidepressant effects.

Zarate et al. (2006) — The Landmark Trial

This NIMH-funded study evaluated 18 TRD patients in a randomized, double-blind, crossover design. Key findings:

  • 71% met response criteria within 24 hours
  • 29% achieved full remission at 24 hours
  • Significant improvement detectable at 2 hours post-infusion
  • Effects lasted approximately 1 week on average

Significance: Established the standard 0.5 mg/kg protocol and provided the strongest early evidence for rapid antidepressant properties.

Large-Scale Studies

Murrough et al. (2013)

This multi-site trial randomized 73 TRD patients to ketamine (0.5 mg/kg) or midazolam (active control). At 24 hours, ketamine showed a significantly greater response rate (64% vs. 28%), effect size 0.81.

Significance: The use of an active control strengthened evidence that ketamine's effects are not merely due to sedation or dissociation.

TRANSFORM Trials (2017-2019)

Janssen conducted five Phase III trials of intranasal esketamine. TRANSFORM-1 did not meet its primary endpoint; TRANSFORM-2 showed significant improvement. SUSTAIN-1 demonstrated ~51% relapse risk reduction with continued treatment.

Significance: Data led to FDA approval of Spravato in 2019.

Recent Developments

Correia-Melo et al. (2024) — IV Ketamine vs. Esketamine (NEJM)

This trial compared IV racemic ketamine with intranasal esketamine in 63 TRD patients. Remission was higher with IV ketamine (32% vs. 16%) at Day 8.

Significance: First direct head-to-head comparison suggesting IV racemic ketamine may be at least as effective as esketamine.

Ketamine for Suicidal Ideation

Multiple studies (Wilkinson et al., 2018; Grunebaum et al., 2018) demonstrated rapid reductions in suicidal ideation within hours. A meta-analysis by Witt et al. (2020) confirmed these rapid anti-suicidal effects are independent of antidepressant effects.

Ongoing Research Areas

  • R-ketamine (arketamine): May have antidepressant effects with fewer dissociative side effects
  • Optimal maintenance protocols: Personalized dosing strategies and long-term schedules
  • Biomarker development: Identifying predictors of treatment response
  • Ketamine-assisted psychotherapy: Combining ketamine with targeted therapy

This article is for informational purposes only. The studies cited are selected highlights, not a comprehensive systematic review.